FOXO4-DRI
A senolytic peptide that selectively targets and eliminates senescent (zombie) cells by disrupting the FOXO4-p53 interaction. Being researched for anti-aging and tissue rejuvenation applications.
Research Status
Early Research
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Redness, mild swelling, or bruising at the injection site. Usually resolves within 24-48 hours. Minimize by rotating sites, allowing solution to reach room temperature, and using proper injection technique.
Mild stinging or soreness during or immediately after injection. Typically resolves within minutes. Reduced by allowing the peptide solution to warm to room temperature before injection.
Repeated injections at the same site can cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Prevent by strictly rotating injection sites with each dose and maintaining at least 1 inch between injection points.
Transient fever, malaise, or mild systemic inflammation may occur as senescent cells are cleared and release inflammatory mediators. This is theoretically possible but not well-documented in human studies. Monitor and contact a healthcare provider if symptoms are severe.
Anaphylaxis or severe allergic reaction is rare but possible with any peptide. Signs include difficulty breathing, facial swelling, severe itching, or rapid heartbeat. Seek emergency medical attention immediately if these occur.
Bacterial infection can occur if sterile technique is not followed. Signs include increasing redness, warmth, pus, or fever. Seek medical attention if infection is suspected.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 5-10 mg |
| Frequency | 3x weekly |
| Timing | Any time of day |
| Route | Topical |
Research compound with limited human data. Dosing protocols vary widely in preclinical studies. Often cycled (e.g., 8 weeks on, 4 weeks off). Topical application concentrations typically 0.1-1% in formulation. Start conservatively and monitor response.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
FOXO4-DRI is a senolytic peptide that disrupts the interaction between the FOXO4 protein and p53 in senescent cells, leading to their selective apoptosis (programmed cell death). Senescent cells accumulate with age and contribute to tissue dysfunction and inflammation. By eliminating these 'zombie' cells, FOXO4-DRI aims to restore tissue homeostasis and support regeneration.
FOXO4-p53 Interaction Disruption
FOXO4-DRI peptide binds to FOXO4 and prevents its interaction with p53, a key tumor suppressor protein. In senescent cells, this interaction normally suppresses p53-mediated apoptosis. By disrupting this interaction, the peptide allows p53 to trigger apoptosis specifically in senescent cells while sparing healthy cells.
Senescent Cell Clearance
Senescent cells express p16 and p21 (cell cycle inhibitors) and accumulate with age. FOXO4-DRI selectively targets these cells for elimination, reducing the senescent cell burden in tissues and decreasing chronic inflammation associated with aging.
Tissue Regeneration and Remodeling
Removal of senescent cells reduces paracrine senescence-associated secretory phenotype (SASP) factors that impair tissue repair. This allows resident stem cells and fibroblasts to function more effectively, supporting collagen synthesis and tissue remodeling.
- FOXO4-DRI selectively targets senescent cells, not healthy cells, due to the FOXO4-p53 dependency in senescent cells
- Senescent cells accumulate with age and secrete pro-inflammatory factors (SASP) that damage surrounding tissue
- Preclinical studies in mice showed improved physical function, increased lifespan, and enhanced tissue regeneration after senolytic treatment
- This is a research-stage compound; human efficacy and safety data are limited
Track your FOXO4-DRI research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. FOXO4-DRI is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.